Trial site
Toronto Memory Program
Toronto, CanadaNot linked to an institution yet
- 11running trials
- 6closed trials
- 0trials confirmed by the site in the last 60 days
- –languages not stated
The site has not confirmed any trial yet.
Running trials
Recruiting
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
NCT07717411· PHASE3· Source
Recruiting
A Post Authorization Registry Study of Participants Treated With LEQEMBI
NCT07762092· Source
Active, not recruiting
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578· PHASE3· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216· PHASE3· Source
Recruiting
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
NCT07177352· PHASE3· Source
Active, not recruiting
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153· PHASE3· Source
Recruiting
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
NCT06584357· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
NCT04777331· PHASE2· Source
Active, not recruiting
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
NCT04639050· PHASE1 PHASE2· Source
Active, not recruiting
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
NCT04468659· PHASE3· Source
Active, not recruiting
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511· PHASE3· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Researchers
No researcher is linked here yet.
Report an error